首页> 美国卫生研究院文献>Diagnostics >Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid Following Combination Chemotherapy with Etoposide Plus COP
【2h】

Clinical Remission in a 72-Year-Old Patient with a Massive Primary Cutaneous Peripheral T-Cell Lymphoma-NOS of the Eyelid Following Combination Chemotherapy with Etoposide Plus COP

机译:72岁患者临床缓解患者含有巨大的主要皮肤外周T细胞淋巴瘤 - 眼睑NOS之后与依托泊苷加上COP组合化疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the rarest subtype of primary cutaneous lymphoma, accounting for approximately 2% of cutaneous lymphomas. The rarity of primary cutaneous PTCL-NOS means that there is a paucity of data regarding clinical and histopathological features and its clinical course. This malignancy is an aggressive and life-threatening hematological malignancy that often presents mimicking other less severe plaque-like skin conditions. Due to the nonspecific nature of these lesions, CD4-positive cutaneous T-cell lymphoma (CTCL) is often misdiagnosed as either mycosis fungoides or Sezary syndrome. We describe a patient who presented with a large tumoral mass in the right frontal area, with involvement of the right upper eyelid and the ocular globe, causing loss of vision greatly impacting the quality of life. Biopsy revealed primary cutaneous PTCL-NOS, treated successfully with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus etoposide combination chemotherapy. As elderly patients are indicated to receive attenuated doses of chemotherapy, CHOP-based regimens represent viable options.
机译:未指定的外周T细胞淋巴瘤(PTCL-NOS)是主要皮肤淋巴瘤的最稀有的亚型,占皮肤淋巴瘤的约2%。主要皮肤pTCL-NOS的罕见性意味着缺乏关于临床和组织病理学特征及其临床过程的数据。这种恶性肿瘤是一种侵略性和危及生命的血液学恶性肿瘤,通常呈现出其他不太严重的斑块状皮肤状况。由于这些病变的非特异性,CD4-阳性皮肤T细胞淋巴瘤(CTCL)通常被误诊为蕈类诱导或SEZARY综合征。我们描述了在右前面积中呈现出大肿瘤肿块的患者,涉及右上眼睑和眼球的患者,导致损失的视力造成极大影响生活质量。活检显示初级皮肤PTCL-NOS,用环磷酰胺,多柔比蛋白,长春螯合物和泼尼松(Chec)加上依托钠组合化疗成功处理。由于老年患者被指示接受减毒剂量的化疗,基于斩波的方案代表可行的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号